T1	Participants 50 100	advanced and recurrent endometrial cancer patients
T2	Participants 252 369	in advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials.
T3	Participants 695 965	Single agent or combination chemotherapy regimens including doxorubicin (A) (12%), doxorubicin/cisplatin (AP) (63%), doxorubicin/paclitaxel (AT) (13%), and paclitaxel/doxorubicin/cisplatin (TAP) (11%) were used among 1203 patients treated on 4 randomized clinical trials
T4	Participants 1140 1158	More S/CC patients
T5	Participants 1178 1293	with advanced stage (III-IV) disease (as opposed to recurrent disease) compared to E patients (45% vs. 24%, p<0.05)
T6	Participants 1681 1735	In patients with advanced/recurrent endometrial cancer
